Has $TRIL ever suggested a reason for WHY its drugs don't bind to human red blood cells?
2017 paper in deck suggests: "association of #CD47 w erythrocyte spectrin cytoskeleton, which results in reduced membrane mobility & failure to cluster CD47 effectively"
$ALXO $IMAB $STTK
2017 paper in deck suggests: "association of #CD47 w erythrocyte spectrin cytoskeleton, which results in reduced membrane mobility & failure to cluster CD47 effectively"
$ALXO $IMAB $STTK
^ Links:
2020 $TRIL slide deck:
https://s22.q4cdn.com/183592819/files/doc_presentations/2020/10/Trillium-Corp-Overview-8-Oct-2020.pdf
2017: https://clincancerres.aacrjournals.org/content/23/4/1068#ref-30
2006:
https://pubmed.ncbi.nlm.nih.gov/16697668/
2003: https://pubmed.ncbi.nlm.nih.gov/12393467/
2020 $TRIL slide deck:
https://s22.q4cdn.com/183592819/files/doc_presentations/2020/10/Trillium-Corp-Overview-8-Oct-2020.pdf
2017: https://clincancerres.aacrjournals.org/content/23/4/1068#ref-30
2006:
https://pubmed.ncbi.nlm.nih.gov/16697668/
2003: https://pubmed.ncbi.nlm.nih.gov/12393467/
^Sentence after that one in the 2017 paper:
"Consistent with this theory, we have previously shown strong binding of $TRIL TTI-621 to human erythrocytes when #CD47 is first preclustered using a nonblocking CD47 antibody"
$ALXO $IMAB $STTK
2014 paper: https://cancerres.aacrjournals.org/content/74/19_Supplement/5011
"Consistent with this theory, we have previously shown strong binding of $TRIL TTI-621 to human erythrocytes when #CD47 is first preclustered using a nonblocking CD47 antibody"
$ALXO $IMAB $STTK
2014 paper: https://cancerres.aacrjournals.org/content/74/19_Supplement/5011